PubMed HealthSearch

PubMed · 52347

[Total transposition of the great vessels: Surgical treatment].

Abstract

One hundred nine cases of complete transposition of great vessels alone or associated to other abnormalities are presented. In 91 cases a palliative treatment is given and in 18 cases there is a total correction done, depending upon the technique. Surgical indication and the technique used in every case is commented, making special reference to transpositions with ductus arteriosus or associated to coarctation of the aorta. In the 18 cases where we have done a total correction, we comment the surgical procedure of one of them who had a subpulmonary stenosis of the fibromuscular type, which we resolved through left ventriculotomy done on the apex of the ventricle and resecting the stenosis with an electroscalpel, which is a technique we have devised.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Cordovilla, F A Díez, J M Brito, J P León, P A Sánchez, V P Martín, C M Bordiú. [Total transposition of the great vessels: Surgical treatment].. https://pubmed.ncbi.nlm.nih.gov/52347/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Treatment of advanced breast cancer with norethisterone acetate.

The medical records of 84 postmenopausal women treated with oral norethisterone acetate (NTA) for advanced breast cancer were retrospectively analyzed. Treatment was devoid of significant toxicity. Twenty-one patients were not evaluable for treatment response either because of insufficient data or inadequate treatment trial. Complete plus partial response was obtained in 21 (33.3%) of the 63 evaluable patients, with a median duration of 10 months. Disease stabilization was observed in 16 (25.4%) patients for a median duration of 5 months, while 26 patients (41.3%) showed progressive disease while on treatment. The best response was observed in women with dominant soft part disease and an age over 70 (CR+PR 48%). The literature on norethisterone acetate is reviewed and compared with present results. The role of progestational agents in the treatment of advanced mammary carcinoma is discussed.

Age Factors